Nucl Med Mol Imaging.  2014 Jun;48(2):130-136.

The Role of 18F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy

Affiliations
  • 1Department of Nuclear Medicine, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemoon-gu, Seoul 120-752, Korea. mdkwj@yuhs.ac
  • 2Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea.
  • 3Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.

Abstract

PURPOSE
To determine whether persisting cervical fluorodeoxyglucose (FDG) uptake after concurrent chemoradiotherapy (CCRT) for cervical cancer can reflect residual malignancy.
METHODS
F-FDG PET/CT was performed before and after CCRT in 136 patients with cervical cancer. The maximum and mean standardized uptake values (SUVmax and SUVmean) were recorded from PET/CT scans performed pre- and post-treatment. SUVs were correlated with treatment response after CCRT. Final treatment response was determined by MRI and further follow-up PET/CT. One hundred four of 136 patients underwent pelvic MRI, and 32 of 136 patients underwent further follow-up PET/CT. Patients were classified into two categories: patients with residual tumor or patients without residual tumor (complete responder). Pre- and post-treatment serum squamous cell carcinoma antigen (SCC) levels were also recorded for comparison. The optimal cutoff value of SUVmax for predicting residual cervical tumor was determined using receiver-operating characteristic (ROC) analysis.
RESULTS
Of 136 patients, 124 showed complete response on further follow-up studies and 12 were confirmed to have residual tumor. The post-treatment SUVmax and pre-/post-treatment SUVmean of complete responders were significantly lower than those of patients with residual tumor: 2.5+/-0.8 and 7.2+/-4.2/1.9+/-0.7 for complete responders and 5.7+/-2.6 and 12.8+/-6.9/3.7+/-0.7 for patients with residual tumor (p<0.05). The pre-treatment SUVmax and pre-/post-treatment serum SCC levels of the complete responders tended to be lower than those of patients with residual tumor, but this did not have statistical significance. Using ROC analysis, an optimal cutoff SUVmax of 4.0 on the post-treatment PET/CT yielded a sensitivity, specificity, positive predictive value, and negative predictive value of 92 %, 94 %, 61 %, and 99 %, respectively (p<0.001).
CONCLUSIONS
Persistent cervical FDG uptake in 18F-FDG PET/CT after CCRT for cervical cancer may be caused by residual tumor or post-therapy inflammation. A higher cutoff SUVmax than conventional criteria for cervical cancer in post-CCRT PET/CT might help to detect residual tumor.

Keyword

Cervical cancer; PET/CT; CCRT; Treatment response

MeSH Terms

Carcinoma, Squamous Cell
Chemoradiotherapy
Fluorodeoxyglucose F18*
Follow-Up Studies
Humans
Inflammation
Magnetic Resonance Imaging
Neoplasm, Residual
Positron-Emission Tomography and Computed Tomography*
ROC Curve
Sensitivity and Specificity
Uterine Cervical Neoplasms*
Fluorodeoxyglucose F18
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr